Home » Get H.E.L.P. Managing Overt HE

Get H.E.L.P. managing overt HE

What is the HE Living Program?

H.E.L.P.—the Hepatic Encephalopathy Living Program—is designed to provide adults living with overt hepatic encephalopathy (HE)* and their caregivers ongoing support for the management of overt HE.

Benefits include:

• 24-hour toll-free hotline for patients, where H.E.L.P. representatives will answer product-related questions
• Co-pay assistance (for eligible patients)
• Educational brochures
• Support to help you stay on treatment—prescription and appointment reminder calls

*Only people ≥18 years of age who are at risk of overt HE recurrence are eligible for this program.

Who can enroll in H.E.L.P.?

As an adult living with overt HE, you are eligible to enroll yourself in H.E.L.P.

If you are caring for a person ≥18 years of age with overt HE, you can also enroll him or her in H.E.L.P. Calling a representative at H.E.L.P. is a great step toward answering any additional questions about H.E.L.P. To reach a H.E.L.P. representative, call 1-866-XIFAXAN (943-2926).

How do I enroll in H.E.L.P.?

Enrolling in H.E.L.P. is easy. If you are a person ≥18 years of age living with overt HE or a caregiver, you can:

• Enroll in H.E.L.P. and download or activate your Xifaxan550 Savings Card by completing the online patient enrollment form
• Call 1-866-XIFAXAN (943-2926)
• Mail in the H.E.L.P. patient enrollment card or fax it to 1-877-953-4389

Enroll in H.E.L.P. and download or activate a Xifaxan550 Savings Card

Learn more about taking Xifaxan 550 mg for overt HE

IMPORTANT SAFETY INFORMATION

XIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥18 years of age. In the trials of XIFAXAN for HE, 91% of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores >25, and only 8.6% of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C).

XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon which may lead to overgrowth of C. difficile. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.

The most common adverse reactions occurring in >8% of patients in the clinical study were edema peripheral (15%), nausea (14%), dizziness (13%), fatigue (12%), ascites (11%), muscle spasms (9%), pruritus (9%), and abdominal pain (9%).

Xifaxan550 is not available for sale outside the U.S.
Xifaxan550 is licensed by Alfa Wassermann S.p.A. to Salix Pharmaceuticals, Inc.

Complete Prescribing Information.

You are encouraged to report negative side effects to the FDA. Visit www.fda.gov/safety/medwatch/ or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
E-mail: Salix@medcomsol.com